RxDoctor Payments Data

Rebecca Meiners, MD

Family Medicine · Baton Rouge, LANPI 1740264514

Payments from drug & device makers

$7,968in general payments, 2019–2025

Across 464 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AbbVie$890
  • Novo Nordisk$769
  • Lilly USA, LLC$722
  • Astellas Pharma US Inc$586
  • Sanofi-aventis U.S. LLC$388
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$7,954100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,968 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$37,071
Medicare patients
111
Services billed
423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide95$110,641
OzempicSemaglutide90$90,495
JardianceEmpagliflozin85$66,692
TrulicityDulaglutide33$41,639
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$33,183
LinzessLinaclotide43$31,699
JanuviaSitagliptin Phosphate27$26,812
EliquisApixaban41$25,368
UbrelvyUbrogepant25$24,241
RybelsusSemaglutide16$22,773
XareltoRivaroxaban16$13,556
MyrbetriqMirabegron26$12,042
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$11,863
Tresiba Flextouch U-100Insulin Degludec23$10,915
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$10,703

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$722$152,279128 claims
Novo NordiskOzempic, Rybelsus$769$113,268106 claims
Boehringer IngelheimJardiance, Combivent Respimat$288$73,25498 claims
AbbVieLinzess, Ubrelvy, Synthroid$890$57,844116 claims
GSKTrelegy Ellipta$1,087$33,18351 claims
MerckJanuvia, Janumet$90$28,72138 claims
PfizerEliquis$81$25,36841 claims
Johnson & JohnsonXarelto$163$13,55616 claims
Astellas Pharma US IncMyrbetriq$586$12,04226 claims
Sanofi-aventis U.S. LLCLantus$388$1,66020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →